Nurix Therapeutics Inc Cash Flow Conversion Efficiency
Nurix Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Nurix Therapeutics Inc (NRIX) has a cash flow conversion efficiency ratio of -0.154x as of August 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-57.38 Million) by net assets ($372.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nurix Therapeutics Inc (2018–2024)
Cash flow conversion efficiency of Nurix Therapeutics Inc from 2018 to 2024. This chart illustrates how Nurix Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Nurix Therapeutics Inc share price for real-time trading data and today's change.
Nurix Therapeutics Inc Cash Flow Conversion Ratio Explained
Nurix Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nurix Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nurix Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Nurix Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mirgor S.A.
BA:MIRG
|
0.025x |
|
Shenyang Jinshan Energy Co Ltd
SHG:600396
|
0.098x |
|
Anhui Heli Co Ltd
SHG:600761
|
0.035x |
|
Guangxi Guitang Group Co Ltd
SHE:000833
|
0.058x |
|
China Wafer Level Csp Co Ltd
SHG:603005
|
0.031x |
|
Arcplus Group PLC
SHG:600629
|
0.035x |
|
La Comer S.A.B. de C.V
MX:LACOMERUBC
|
0.033x |
|
Hebei Huatong Wires and Cables Group Co. Ltd.
SHG:605196
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Nurix Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Nurix Therapeutics Inc from 2018 to 2024. Review Nurix Therapeutics Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-11-30 | $526.99 Million | $-172.58 Million | -0.327x | +19.30% |
| 2023-11-30 | $200.49 Million | $-81.36 Million | -0.406x | +22.88% |
| 2022-11-30 | $303.70 Million | $-159.81 Million | -0.526x | -113.50% |
| 2021-11-30 | $342.30 Million | $-84.36 Million | -0.246x | -89325.95% |
| 2020-11-30 | $290.27 Million | $-80.00K | 0.000x | +99.56% |
| 2019-11-30 | $-9.52 Million | $601.00K | -0.063x | +97.74% |
| 2018-11-30 | $11.35 Million | $-31.68 Million | -2.791x | -- |
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-ce… Read more